Table 3. Overall and bladder cancer-specific survival as a function of baseline demographic, clinical and pathological features in the entire cohort, as well as stratified by disease invasiveness.

Variable	Category	No. (%) of patients	Overall survival		Cancer-specific survival
			P-value	Unadjusted HR (95% CI)	P-value	Unadjusted HR (95% CI)
Entire cohort (n = 528)
Gender	Male	479 (90.7)
	Female	49 (9.3)	0.257	0.78 (0.51–1.19)	0.197	1.42 (0.83–2.44)
Age (years)	< 60	198 (37.5)
	60–69	172 (32.6)	< 0.001	1.92 (1.38–2.68)	0.128	1.39 (0.91–2.12)
	> 69	158 (29.9)	< 0.001	3.83 (2.77–5.30)	< 0.01	1.95 (1.28–2.96)
Stage	0	155 (29.4)
	I	223 (42.2)	< 0.001	2.00 (1.37–2.92)	< 0.05	3.34 (1.27–8.79)
	II	58 (11.0)	< 0.001	2.71 (1.67–4.39)	< 0.001	15.61 (5.96–40.93)
	III	24 (4.5)	< 0.001	9.73 (5.69–16.63)	< 0.001	48.53 (18.13–129.92)
	IV	68 (12.9)	< 0.001	18.81 (12.33–28.69)	< 0.001	97.25 (38.72–244.24)
Tumour grade	Low (I, II)	263 (49.8)
	High (III, IV)	265 (50.2)	< 0.001	3.40 (2.60–4.45)	< 0.001	12.23 (7.02–21.30)
Comorbidity	0	225 (42.6)
	1	132 (25.0)	0.202	1.23 (0.89–1.70)	0.309	1.26 (0.81–1.94)
	2, 3	171 (32.4)	< 0.001	1.87 (1.40–2.51)	< 0.01	1.70 (1.15–2.53)
Superficial bladder cancer (n = 378)
Age (years)	< 60	142 (37.6)
	60–69	122 (32.3)	<0.001	2.90 (1.73–4.85)	0.308	1.67 (0.62–4.50)
	> 69	114 (30.2)	< 0.001	7.99 (4.89–13.07)	< 0.01	3.83 (1.49–9.82)
Comorbidity	0	166 (43.9)
	1	96 (25.4)	0.400	1.20 (0.78–1.85)	0.563	1.28 (0.55–2.97)
	2, 3	116 (30.7)	< 0.01	1.76 (1.18–2.64)	0.556	0.74 (0.28–1.98)
Invasive bladder cancer (n = 102)
Age (years)	< 60	42 (41.2)
	60–69	36 (35.3)	0.088	1.63 (0.93–2.86)	0.071	1.74 (0.95–3.17)
	> 69	24 (23.5)	< 0.05	2.24 (1.21–4.13)	< 0.05	2.07 (1.08–3.96)
Comorbidity	0	44 (43.1)
	1	25 (24.5)	0.691	1.13 (0.61–2.09)	0.741	1.12 (0.57–2.19)
	2, 3	33 (32.4)	< 0.05	1.78 (1.02–3.11)	< 0.05	1.90 (1.07–3.40)
Radical cystectomy	Yes	58 (56.9)
	No	44 (43.1)	0.086	1.52 (0.94–2.44)	0.206	1.39 (0.84–2.31)

Abbreviations: HR, hazard ratio; CI, confidence interval.